Enlivex Therapeutics Ltd - Asset Resilience Ratio

Latest as of September 2025: 67.44%

Enlivex Therapeutics Ltd (ENLV) has an Asset Resilience Ratio of 67.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

ILA14.12 Million

≈ $37.86K USD Cash + Short-term Investments

Total Assets

ILA20.94 Million

≈ $56.13K USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Enlivex Therapeutics Ltd's Asset Resilience Ratio has changed over time. Check ENLV strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Enlivex Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Enlivex Therapeutics Ltd market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA14.12 Million	67.44%
Total Liquid Assets	ILA14.12 Million	67.44%

Asset Resilience Insights

Very High Liquidity: Enlivex Therapeutics Ltd maintains exceptional liquid asset reserves at 67.44% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Enlivex Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Enlivex Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Genfit S.A. PA:GNFT	Biotechnology	64.01%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	22.98%
Altimmune Inc NASDAQ:ALT	Biotechnology	82.06%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Jiangsu GDK Biotechnology Co Ltd SHG:688670	Biotechnology	9.82%

Annual Asset Resilience Ratio for Enlivex Therapeutics Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Enlivex Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	72.94%	ILA20.20 Million ≈ $54.14K	ILA27.69 Million ≈ $74.23K	+0.97pp
2023-12-31	71.97%	ILA26.51 Million ≈ $71.06K	ILA36.83 Million ≈ $98.74K	+71.53pp
2022-12-31	0.44%	ILA299.00K ≈ $801.61	ILA67.64 Million ≈ $181.35K	-76.21pp
2021-12-31	76.65%	ILA72.93 Million ≈ $195.52K	ILA95.15 Million ≈ $255.08K	+2.23pp
2020-12-31	74.42%	ILA30.03 Million ≈ $80.52K	ILA40.36 Million ≈ $108.20K	+28.52pp
2019-12-31	45.90%	ILA8.06 Million ≈ $21.61K	ILA17.56 Million ≈ $47.08K	+45.54pp
2018-12-31	0.36%	ILA40.00K ≈ $107.24	ILA11.03 Million ≈ $29.58K	--

pp = percentage points

About Enlivex Therapeutics Ltd

TA:ENLV Israel Biotechnology

Market Cap

$2.98 Million

ILA1.11 Billion ILA

Market Cap Rank

#29495 Global

#432 in Israel

Share Price

ILA4.68

Change (1 day)

-31.78%

52-Week Range

ILA0.57 - ILA614.90

All Time High

ILA14150.00